Understand the source comparison
NF-kB Pathway Anti-Inflammatory Peptides: Comparison by Mechanism
IKK Inhibitory Peptides Block IKKβ ATP-binding or IKKγ interaction High. Selectively inhibits canonical NF-kB without affecting JNK/p38 MAPK pathways 1.5–6.8 hours (depending on cyclisation) Cell-penetrating peptide (CPP) conjugation required Most clinically a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- IKK Inhibitory Peptides
- Block IKKβ ATP-binding or IKKγ interaction
- High. Selectively inhibits canonical NF-kB without affecting JNK/p38 MAPK pathways
- 1.5–6.8 hours (depending on cyclisation)
- Cell-penetrating peptide (CPP) conjugation required
- Most clinically advanced. NBD peptides in Phase II trials for inflammatory arthritis
- IκB-Mimetic Peptides
- Bind NF-kB Rel homology domain, prevent nuclear translocation
- Moderate. Can affect non-canonical pathway if p52/RelB dimers are targeted
- 2–4 hours (linear), 8–12 hours (stapled)
- CPP or lipid nanoparticle encapsulation
- Best for systemic inflammation. Preserves pathogen response better than IKK inhibitors
- DNA-Binding Inhibitors
- Compete with NF-kB for κB-site promoter binding
- Low. Potential off-target effects on other transcription factors with similar DNA motifs
- 1–3 hours (highly susceptible to nucleases)
- Nuclear localisation signal (NLS) plus CPP required
- Experimental only. Nuclear delivery remains a technical barrier
- Peptide-Drug Conjugates
- Peptide targets NF-kB; conjugated small molecule provides additional anti-inflammatory activity
- Variable. Depends on conjugated molecule
- Depends on linker chemistry (2–24 hours)
- Receptor-mediated endocytosis or CPP
- Emerging approach. Combines NF-kB inhibition with COX-2 or LOX inhibition for synergistic effect